IN THIS ISSUE
Value-Based Tools
Michael D. Dalzell
Outcomes-based contracting for drugs is ready for the mainstream. Before they jump in, insurers and pharma need to solve data puzzles and outcomes conundrums.
Viewpoint
Zachary Hafner

Zachary Hafner
Advisory Board

Viewpoint
Carter Paine

Carter Paine
naviHealth

Neither providers nor health plans have had an incentive to manage post-acute care. That’s changing. Metrics and predictive analytics can help.
Tomorrow’s Medicine
Thomas Morrow, MD
The new Merck drug could help stem the tide of hypervirulent C. difficile, but it’s expected to be expensive.
News & Commentary
News & Commentary